Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema

被引:5
|
作者
Yozgat, Zubeyir [1 ]
Dogan, Mustafa [1 ]
Sabaner, Mehmet Cem [1 ]
Gobeka, Hamidu Hamisi [2 ]
Yazgan Akpolat, Serpil [3 ]
机构
[1] Afyonkarahisar Hlth Sci Univ, Afyon, Turkey
[2] Ibrahim Cecen Univ Agri, Agri Merkez, Turkey
[3] Malatya Inonu Univ, Malatya, Turkey
关键词
Aflibercept; Diabetic macular edema; Fundus fluorescein angiography; Microperimetry; Multifocal electroretinography; Optical coherence tomography;
D O I
10.1007/s10792-021-01737-w
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To evaluate anatomical and neuroretinal functional aspects in patients with diabetic macular edema (DME) after intravitreal anti-vascular endothelial growth factor (VEGF) therapy, in particular aflibercept. Materials and methods This prospective single-centered interventional study was performed at Afyonkarahisar Health Science University Faculty of Medicine, Department of Ophthalmology, where 32 eyes of 32 patients with DME were investigated. All patients received five intravitreal aflibercept injections on a monthly basis and were followed up for >= 6 months. After a comprehensive ophthalmological examination, including the measurements of visual acuity and intraocular pressure, and an antero-posterior segment slit-lamp biomicroscopy before and after full pupil dilation, fundus fluorescein angiography and optical coherence tomography were performed at baseline and during the third and sixth months post-therapy. Microperimetry and multifocal electroretinography were also performed at baseline and during the sixth months. Results Mean visual acuity increased from 0.73 to 0.57 and 0.33 logarithm of the minimum angle of resolution (logMAR) during the third and sixth months, respectively (p < 0.001). Changes in intraocular pressure were not statistically significant (p = 0.472). There was statistically significantly decreased mean central macular thickness from 390.2 mu m to 242.6 and 289.7 mu m during the third and sixth months, respectively (p < 0.001). Significantly improved fixation patterns during the sixth month, along with significantly increased macular sensitivity from 8.2 to 14.2 dB (p < 0.001) and significantly decreased local deficit from - 10.3 to 5.5 dB (p < 0.001) were observed. Further, there was a significantly increased N1 amplitude in the first ring and significantly increased P1 amplitude in all rings (p for each parameter < 0.05). There was also significantly decreased N1 wave implicit time in all rings and significantly decreased P1 wave in the second, third, fourth and fifth rings (p for each parameter < 0.05). Conclusions Patients with DME showed profound improvement in the retinal neurophysiological function, which was also accompanied by anatomical and ultrastructural integrity recovery after intravitreal aflibercept therapy. In the pathogenesis of DME, the influence of neurodegeneration has been increasingly gaining significant attention. Consequently, the need to assess neurophysiological effects of anti-VEGF therapy using a variety of diagnostic measures like electrophysiological studies and multimodal imaging technologies is undeniably growing.
引用
收藏
页码:1783 / 1798
页数:16
相关论文
共 50 条
  • [1] Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema
    Zübeyir Yozgat
    Mustafa Doğan
    Mehmet Cem Sabaner
    Hamidu Hamisi Gobeka
    Serpil Yazgan Akpolat
    International Ophthalmology, 2021, 41 : 1783 - 1798
  • [2] Intravitreal Anti-VEGF Therapy in the Management of Diabetic Macular Edema
    Vaziri K.
    Fortun J.A.
    Current Ophthalmology Reports, 2016, 4 (2) : 49 - 55
  • [3] Anti-VEGF Therapy for Diabetic Macular Edema
    Stewart, Michael W.
    CURRENT DIABETES REPORTS, 2014, 14 (08)
  • [4] Compliance and adherence of patients with diabetic macular edema to intravitreal Anti-VEGF therapy
    Weiss, Maximilian
    Herold, Tina
    Schumann, Ricarda
    Liegl, Raffael
    Muller, Michael
    Babenko, Alexander
    Rottmann, Miriam
    Schiefelbein, Johannes
    Priglinger, Siegfried
    Kortuem, Karsten Ulrich
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [5] Anti-VEGF Therapy for Diabetic Macular Edema
    Michael W. Stewart
    Current Diabetes Reports, 2014, 14
  • [6] Retinal Vasculature Changes in Patients with Diabetic Macular Edema treated with Intravitreal Anti-VEGF
    Berdia, Jay
    Levine, Jonathan
    Johnson, Brandon B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [7] Intravitreal anti-VEGF treatment for refractory diabetic macular edema
    Papavasileiou, E.
    Quijano, C.
    Younis, S.
    ACTA OPHTHALMOLOGICA, 2015, 93
  • [8] Anti-VEGF Therapy for the Management of Diabetic Macular Edema
    Rodriguez M.
    Storey P.
    Do D.V.
    Current Ophthalmology Reports, 2013, 1 (3) : 122 - 127
  • [9] Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review
    Vitiello, Livio
    Salerno, Giulio
    Coppola, Alessia
    De Pascale, Ilaria
    Abbinante, Giulia
    Gagliardi, Vincenzo
    Lixi, Filippo
    Pellegrino, Alfonso
    Giannaccare, Giuseppe
    LIFE-BASEL, 2024, 14 (06):
  • [10] Intravitreal Steroids Compared with Anti-VEGF Treatment for Diabetic Macular Edema
    Patil, Nikhil S.
    Mihalache, Andrew
    Hatamnejad, Amin
    Popovic, Marko M.
    Kertes, Peter J.
    Muni, Rajeev H.
    OPHTHALMOLOGY RETINA, 2023, 7 (04): : 289 - 299